TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01091844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voiding Trial
Description: After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Voiding Trial
Description: After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
Study: NCT05743114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elemind Neuromodulation (ENMod)
Description: The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elemind Neuromodulation (ENMod)
Description: The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
Study: NCT02824029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00393198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytotec
Description: Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
Study: NCT03638401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
Description: This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
Study: NCT03792035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo
Description: tid, po.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: tid, po.
Study: NCT03364283

Intervention type: PROCEDURE
Intervention: Surgical position
Study: NCT01116453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
Study: NCT02898428

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM)
Study: NCT03364803

Intervention type: OTHER
Intervention: Trait Food Craving Questionnaire-Trait (FCQ-T)
Description: Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.

Intervention type: OTHER
Intervention: Visual Analogue Scale (VAS)
Description: A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark.

Intervention type: OTHER
Intervention: Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
Description: A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
Study: NCT04206813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9 2 dose regimen
Description: a 2-dose regimen of Gardasil 9 at 0 and 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil 9 3 dose regimen
Description: standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9 rescue dose
Description: A rescue dose of Gardasil 9 will be given at 12 months
Study: NCT03007030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03695497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Description: total hip arthroplasty with DAA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Lateral Approach
Description: total hip arthroplasty with DLA
Study: NCT03727555

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intrathecal and intravenous LV gene therapy
Description: Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 multiplicity of infection/ml which carry normal ABCD1 gene
Study: NCT01116453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
Study: NCT02503839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: cyclooxygenase-2 inhibitor. Anti-inflammatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: cyclooxygenase-2 inhibitor. Anti-inflammatory

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: Therapeutic and prophylactic TB vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: Therapeutic and prophylactic TB vaccine
Study: NCT02519270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGN002
Description: IGN002 is a monoclonal antibody fusion protein.
Study: NCT04297839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate Anticoagulation Solution
Description: Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (heparin or continuous saline)
Description: Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
Study: NCT01502202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed plusCIsplatin
Description: Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed plusCIsplatin
Description: Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
Study: NCT01521221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand grip maneuver
Description: Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
Study: NCT00003571

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: tumor replication error analysis
Study: NCT04140500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669
Description: Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7247669
Description: Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
Study: NCT00837863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: ALTU-238 0.3 mg/kg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: ALTU-238 0.6 mg/kg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: ALTU-238 0.9 mg/kg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Nutropin AQ 0.043 mg/kg daily
Study: NCT02510495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 180 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 300 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
Study: NCT00529399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum
Description: Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum and Aluminum hydroxide
Description: Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum hydroxide
Description: Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
Study: NCT03347968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: All participants will receive MEDI0382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: All participants will receive Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: All participants will receive Esmolol
Study: NCT04298593

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiostat
Description: This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
Study: NCT00909012

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: high oleic sunflower oil
Description: placebo, which does not provide DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
Study: NCT01027546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
Study: NCT03565887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 ophthalmic solution 0.1%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: Vehicle placebo ophthalmic solution
Study: NCT03453268

Intervention type: OTHER
Group type: OTHER
Intervention: STEP DOWN strategy
Description: reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: usual treatment
Study: NCT03173040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiuBangZi pill or NiuBangZi pill placebo
Description: For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NiuBangZi pill or NiuBangZi pill placebo
Description: For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
Study: NCT05599828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Tablet
Study: NCT03244020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325 mg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325 mg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325 mg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Description: Enoxaparin 40 mg subcutaneous injection once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Description: Enoxaparin 40 mg subcutaneous injection once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Description: Enoxaparin 40 mg subcutaneous injection once daily
Study: NCT04088838

Intervention type: OTHER
Intervention: Pain tracking app
Description: In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
Study: NCT00605280

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard of Care
Description: Clinicians decision to use optional laser therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen
Description: Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
Study: NCT01737580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resiquimod

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Study: NCT03712644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR-guided coronary revascularization
Description: Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
Study: NCT02660034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Study: NCT01212952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Optional correlative studies
Study: NCT02234869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIB017 (Peginterferon beta-1a)
Description: Single-use, disposable, prefilled pen for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (Peginterferon beta-1a)
Description: Single-use, disposable, prefilled pen for subcutaneous injection
Study: NCT03609762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L HRQOL results be available to the attending doctor
Description: all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
Study: NCT02053818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
Study: NCT02008474

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + incentives for behavior 3 months
Description: Participants will receive monetary incentives for submitting their behavior change information into a study website

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + incentives for weight loss at month 3
Description: Participants will receive an incentive for meeting their weight loss goal at month 3.
Study: NCT02053818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
Study: NCT02008474

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + Incentives for behavior 12 months
Description: Participants will receive incentives for submitting behavior change information over the course of 12 months.